Novavax Inc
Novavax Inc (NVAX) Historical Volatility
NVAX's 30 day historical volatility is 87.96%, in the 83rd percentile of readings over the past year. This is a high percentile, meaning Novavax Inc shares have swung far more than usual. NVAX's 30 day implied volatility sits at 76.56%, with an IV Rank of 31.94%, leaving IV 11.40 points below historical volatility. This means options are pricing in less movement than the stock has actually delivered, as of Nov 20, 2026.
Read more
Tracking NVAX historical volatility helps you see how much Novavax Inc's stock price has actually moved, giving you a baseline for whether option premiums look fair, cheap, or expensive. While implied volatility shows what the market expects, NVAX's HV, also known as realized volatility, shows what actually happened. Use our scanner to monitor NVAX 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.
Historical volatility is the annualized standard deviation of a stock's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. NVAX's 30 day historical volatility, or NVAX HV, is one of the most widely watched readings because it balances responsiveness with stability. Comparing NVAX's HV to its implied volatility reveals the volatility risk premium. When IV sits well above HV, options are pricing in more movement than the stock has actually delivered, giving option sellers an edge. When HV runs hot relative to IV, options are pricing in less movement than the stock has delivered, and buyers may be underpaying for it.
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics.
Historical Volatility
Historical movement is elevated versus the past year. The stock has been unusually active.
As of Nov 20, 2026
As of Nov 20, 2026
As of Nov 20, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →